The model of this well-financed two-year-old start-up harks back to the mid-to-late 1990s when technology promised to provide industrial-age solutions to the handcraft of drug R&D. Its investor list likewise recalls earlier years: one of its key venture funds, Kleiner Perkins, once at the forefront of biotech investing has largely remained on the sidelines since the mid-1990s. Even its vocabulary echoes older ambitions--FivePrime aims to mine the pharmanome, just as companies in the late 1990s aimed to mine the proteome, peptidome, metabolome, cytome, glycome and cellome.
951 Gateway Boulevard
South San Francisco, CA 94080
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
After a second quarter of declining Elevidys sales following two deaths of DMD patients treated with the gene therapy, Sarepta is cutting costs to fund remaining programs and meet debt requirements.
Plus deals involving Novartis/Sironax, Neuraxpharm/Dizlin, Recursion/RallyBio, MaaT/Clinigen, Future Pak/Theratechnologies, BerGenBio/Oncoinvent, Xoma/Turnstone and more.
Stelara revenues declined 42.7% in the quarter due to biosimilars, but innovative medicines grew 4.9%, surpassing $15bn for the quarter. Although pharma tariffs could be coming, the firm said the impact continues to be hard to predict.
After a second quarter of declining Elevidys sales following two deaths of DMD patients treated with the gene therapy, Sarepta is cutting costs to fund remaining programs and meet debt requirements.
Plus deals involving Novartis/Sironax, Neuraxpharm/Dizlin, Recursion/RallyBio, MaaT/Clinigen, Future Pak/Theratechnologies, BerGenBio/Oncoinvent, Xoma/Turnstone and more.
Stelara revenues declined 42.7% in the quarter due to biosimilars, but innovative medicines grew 4.9%, surpassing $15bn for the quarter. Although pharma tariffs could be coming, the firm said the impact continues to be hard to predict.